Investment
Features
FeesSafety
Academy
More
Pluang+

IBEX posts record Q4 revenue and strong full-year 2026 growth, driven by AI and HealthTech sectors.

Company Fundamentals
11 Sep 2026
Danny Green
View Source
Bullish
IBEX posts record Q4 revenue and strong full-year 2026 growth, driven by AI and HealthTech sectors.

IBEX Limited reported a record fourth-quarter revenue of $164.27 million, surpassing estimates, with an 11.6% year-over-year increase marking its sixth consecutive quarter of double-digit growth. The company's adjusted earnings per share met analyst expectations at $0.85, supported by strong performance in HealthTech, technology, travel, logistics, retail, e-commerce, and AI-powered Wave iX solutions. Despite some declines in profitability measures due to training costs and operational shifts, full-year 2026 results showed a 15.4% revenue increase to $644.10 million and a 25.7% rise in net income to $46.30 million. IBEX also achieved record operating cash flow of $59 million and ended the fiscal year with $30.90 million in net cash, highlighting robust financial health and growing demand for its AI customer-experience services.

More News

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...

Analyst Insights
Neutral
1 hour ago
Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...

Market News
Bearish
1 hour ago
Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...

Analyst Insights
Bullish
2 hours ago
Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...

Analyst Insights
Bullish
3 hours ago
Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App